What is the maximum recommended dose of spironolactone (aldosterone antagonist)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Recommended Dose of Spironolactone

The maximum recommended dose of spironolactone is 400 mg daily for patients with cirrhosis and ascites, and 50 mg daily for heart failure patients. 1, 2

Indication-Specific Maximum Dosing

Cirrhosis with Ascites

  • Initial dose typically starts at 100 mg daily, which can be progressively increased in a stepwise fashion 1
  • Dose increases should occur every 3-5 days (maintaining a 100 mg spironolactone:40 mg furosemide ratio when used in combination) 1
  • Maximum dose is 400 mg daily for management of ascites in cirrhosis 1
  • When combined with furosemide, the maximum recommended doses are 400 mg/day of spironolactone and 160 mg/day of furosemide 1, 3

Heart Failure

  • Initial dose is 25 mg daily for heart failure patients with normal renal function 1, 2
  • Maximum recommended dose is 50 mg daily for heart failure patients 1, 2
  • For patients with eGFR between 30-50 mL/min/1.73m², consider lower dosing (12.5-25 mg daily or every other day) 2, 4
  • Spironolactone is contraindicated in patients with eGFR <30 mL/min/1.73m² due to risk of hyperkalemia 2

Primary Hyperaldosteronism

  • Doses of 100 mg to 400 mg daily are recommended in preparation for surgery 4
  • For long-term maintenance therapy in patients unsuitable for surgery, the lowest effective dose should be used 4

Essential Hypertension

  • Initial daily dose is 25 mg to 100 mg 4
  • Doses greater than 100 mg/day generally do not provide additional blood pressure reduction 4, 5

Monitoring and Safety Considerations

Dose Titration

  • When increasing doses, allow at least 72 hours between dose adjustments due to spironolactone's long half-life 1
  • For cirrhosis, monitor spot urine sodium/potassium ratio to guide dosing (ratio >1 indicates effective natriuresis) 1
  • For heart failure, recheck renal function and electrolytes 1 and 4 weeks after starting treatment or increasing dose 1

Adverse Effects Monitoring

  • Monitor serum potassium and renal function closely, especially during the first month of treatment 1, 2
  • If potassium rises to >5.5 mmol/L, reduce dose by half; if >6.0 mmol/L, discontinue immediately 1, 2
  • If creatinine rises to >220 μmol/L (2.5 mg/dL), reduce dose; if >310 μmol/L (3.5 mg/dL), discontinue 1
  • Gynecomastia occurs in approximately 10% of men, especially at higher doses 1, 2, 6
  • Consider switching to eplerenone in men experiencing gynecomastia 1, 2

Special Considerations

  • In patients with renal impairment, lower maximum doses are recommended 1, 2
  • Discontinue spironolactone if severe hyponatremia (serum sodium <120 mmol/L), progressive renal failure, worsening hepatic encephalopathy, or incapacitating muscle cramps occur 1
  • For patients with cirrhosis, initiate therapy in a hospital setting and titrate slowly 4
  • There appears to be no additional benefit for doses above 50 mg/day for hypertension 5
  • High-dose spironolactone (75-300 mg) has been studied in acute heart failure with favorable decongestion outcomes and acceptable safety profile 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Spironolactone Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of cirrhotic ascites.

Acta gastro-enterologica Belgica, 2007

Research

Spironolactone for hypertension.

The Cochrane database of systematic reviews, 2010

Research

Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.